The fourth International Conference on Harmonization of TechnicalRequirements for Registration of Pharmaceuticals for Human Use, held in Brussels, Belgium, July 16-18, heard how non-ICH countries view the impact and implementation of the ICH guidelines.
Juhana Idanpaan-Heikkila, director, division of drug management and policies in the World Health Organization, described the discussions on these issues which took place at the WHO's eighth International Conference of Drug Regulatory Agencies in Bahrain last November.
Reviewing the progress made by the ICH and its relevance to and implementation in over 170 countries which do not participate in the ICH process, delegates at ICDRA agreed that ICH has "unique merits." Moreover, said Dr Idanpaan-Heikkila, the WHO has strongly advocated that the scheme should be extended beyond its current 17 members to include all 191 of the WHO's member states.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze